Targeted Therapies for Medullary Thyroid Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 徐德全 ,  代文杰

哈爾濱醫科大學附屬第一醫院甲狀腺乳腺細胞移植外科（黑龍江哈爾濱 150001）;

Corresponding?author：

代文杰, Email: davidhmu@163.com

Keywords：

甲狀腺髓樣癌; 靶向治療

DOI：

10.7507/1007-9424.20140376

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 徐德全, 代文杰. Targeted Therapies for Medullary Thyroid Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(12): 1579-1582. doi: 10.7507/1007-9424.20140376 Copy

1.	Wartofsky L.Increasing world incidence of thyroid cancer:incre-ased detection or higher radiation exposure?[J].Hormones (Athens), 2010, 9(2):103-108.
2.	Kazaure HS, Roman SA, Sosa JA.Medullary thyroid microcarcinoma:a population-level analysis of 310 patients[J].Cancer, 2012, 118(3):620-627.
3.	Sippel RS, Kunnimalaiyaan M, Chen H.Current management of medullary thyroid cancer[J].Oncologist, 2008, 13(5):539-547.
4.	Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, et al.Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma[J].Anticancer Res, 2011, 31(12):4179-4183.
5.	de Groot JW, Links TP, Plukker JT, et al.RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors[J].Endocr Rev, 2006, 27(5):535-560.
6.	馬維昌, 代文杰.遺傳性甲狀腺髓樣癌的診斷及外科處理[J].外科理論與實踐, 2013, 18(6):586-589.
7.	陳曦, 李宏為.遺傳性甲狀腺癌[J].中國實用外科雜志, 2010, 30(10):828-830.
8.	Elisei R, Cosci B, Romei C, et al.Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:a 10-year follow-up study[J].J Clin Endocrinol Metab, 2008, 93(3):682-687.
9.	Segouffin-Cariou C, Billaud M.Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway[J].J Biol Chem, 2000, 275(5):3568-3576.
10.	Sherman SI.Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers[J].J Clin Endocrinol Metab, 2009, 94(5):1493-1499.
11.	Guleng B, Tateishi K, Ohta M, et al.Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner[J].Cancer Res, 2005, 65(13):5864-5871.
12.	吳生華, 俞繼衛, 鄭林海, 等.CNTN-1、VEGF-C和VEGFR-3在胃癌組織中的表達及其臨床意義[J].中國普外基礎與臨床雜志, 2011, 18(2):142-148.
13.	Gild ML, Bullock M, Robinson BG, et al.Multikinase inhibitors:a new option for the treatment of thyroid cancer[J].Nat Rev Endocrinol, 2011, 7(10):617-624.
14.	National Comprehensive Cancer Network.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology:thyroid carcinoma.Version 2.2013[EB/OL].2014-03-01. http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
15.	Wedge SR, Ogilvie DJ, Dukes M, et al.ZD6474 inhibits vasc-ular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration[J].Cancer Res, 2002, 62(16):4645-4655.
16.	Carlomagno F, Vitagliano D, Guida T, et al.ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases[J].Cancer Res, 2002, 62(24):7284-7290.
17.	Haraldsdottir S, Shah MH.An update on clinical trials of targeted therapies in thyroid cancer[J].Curr Opin Oncol, 2014, 26(1):36-44.
18.	Wells SA Jr, Gosnell JE, Gagel RF, et al.Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer[J].J Clin Oncol, 2010, 28(5):767-772.
19.	Robinson BG, Paz-Ares L, Krebs A, et al.Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer[J].J Clin Endocrinol Metab, 2010, 95(6):2664-2671.
20.	Wells SA Jr, Robinson BG, Gagel RF, et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized, double-blind phaseⅢtrial[J].J Clin Oncol, 2012, 30(2):134-141.
21.	Leboulleux S, Bastholt L, Krause T, et al.Vandetanib in locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 2 trial[J].Lancet Oncol, 2012, 13(9):897-905.
22.	Kurzrock R, Sherman SI, Ball DW, et al.Activity of XL184(Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer[J].J Clin Oncol, 2011, 29(19):2660-2666.
23.	Yakes FM, Chen J, Tan J, et al.Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth[J].Mol Cancer Ther, 2011, 10(12):2298-2308.
24.	Elisei R, Schlumberger MJ, Müller SP, et al.Cabozantinib in progressive medullary thyroid cancer[J].J Clin Oncol, 2013, 31(29):3639-3646.
25.	Ahmed M, Barbachano Y, Riddell A, et al.Analysis of the efficacy and toxicity of sorafenib in thyroid cancer:a phaseⅡstudy in a UK based population[J].Eur J Endocrinol, 2011, 165(2):315-322.
26.	Schlumberger MJ, Elisei R, Bastholt L, et al.PhaseⅡstudy of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer[J].J Clin Oncol, 2009, 27(23):3794-3801.
27.	Cohen EE, Rosen LS, Vokes EE, et al.Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer:results from a phaseⅡstudy[J].J Clin Oncol, 2008, 26(29):4708-4713.

1. Wartofsky L.Increasing world incidence of thyroid cancer:incre-ased detection or higher radiation exposure?[J].Hormones (Athens), 2010, 9(2):103-108.
2. Kazaure HS, Roman SA, Sosa JA.Medullary thyroid microcarcinoma:a population-level analysis of 310 patients[J].Cancer, 2012, 118(3):620-627.
3. Sippel RS, Kunnimalaiyaan M, Chen H.Current management of medullary thyroid cancer[J].Oncologist, 2008, 13(5):539-547.
4. Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, et al.Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma[J].Anticancer Res, 2011, 31(12):4179-4183.
5. de Groot JW, Links TP, Plukker JT, et al.RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors[J].Endocr Rev, 2006, 27(5):535-560.
6. 馬維昌, 代文杰.遺傳性甲狀腺髓樣癌的診斷及外科處理[J].外科理論與實踐, 2013, 18(6):586-589.
7. 陳曦, 李宏為.遺傳性甲狀腺癌[J].中國實用外科雜志, 2010, 30(10):828-830.
8. Elisei R, Cosci B, Romei C, et al.Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer:a 10-year follow-up study[J].J Clin Endocrinol Metab, 2008, 93(3):682-687.
9. Segouffin-Cariou C, Billaud M.Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway[J].J Biol Chem, 2000, 275(5):3568-3576.
10. Sherman SI.Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers[J].J Clin Endocrinol Metab, 2009, 94(5):1493-1499.
11. Guleng B, Tateishi K, Ohta M, et al.Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner[J].Cancer Res, 2005, 65(13):5864-5871.
12. 吳生華, 俞繼衛, 鄭林海, 等.CNTN-1、VEGF-C和VEGFR-3在胃癌組織中的表達及其臨床意義[J].中國普外基礎與臨床雜志, 2011, 18(2):142-148.
13. Gild ML, Bullock M, Robinson BG, et al.Multikinase inhibitors:a new option for the treatment of thyroid cancer[J].Nat Rev Endocrinol, 2011, 7(10):617-624.
14. National Comprehensive Cancer Network.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology:thyroid carcinoma.Version 2.2013[EB/OL].2014-03-01. http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.
15. Wedge SR, Ogilvie DJ, Dukes M, et al.ZD6474 inhibits vasc-ular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration[J].Cancer Res, 2002, 62(16):4645-4655.
16. Carlomagno F, Vitagliano D, Guida T, et al.ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases[J].Cancer Res, 2002, 62(24):7284-7290.
17. Haraldsdottir S, Shah MH.An update on clinical trials of targeted therapies in thyroid cancer[J].Curr Opin Oncol, 2014, 26(1):36-44.
18. Wells SA Jr, Gosnell JE, Gagel RF, et al.Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer[J].J Clin Oncol, 2010, 28(5):767-772.
19. Robinson BG, Paz-Ares L, Krebs A, et al.Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer[J].J Clin Endocrinol Metab, 2010, 95(6):2664-2671.
20. Wells SA Jr, Robinson BG, Gagel RF, et al.Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer:a randomized, double-blind phaseⅢtrial[J].J Clin Oncol, 2012, 30(2):134-141.
21. Leboulleux S, Bastholt L, Krause T, et al.Vandetanib in locally advanced or metastatic differentiated thyroid cancer:a randomised, double-blind, phase 2 trial[J].Lancet Oncol, 2012, 13(9):897-905.
22. Kurzrock R, Sherman SI, Ball DW, et al.Activity of XL184(Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer[J].J Clin Oncol, 2011, 29(19):2660-2666.
23. Yakes FM, Chen J, Tan J, et al.Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth[J].Mol Cancer Ther, 2011, 10(12):2298-2308.
24. Elisei R, Schlumberger MJ, Müller SP, et al.Cabozantinib in progressive medullary thyroid cancer[J].J Clin Oncol, 2013, 31(29):3639-3646.
25. Ahmed M, Barbachano Y, Riddell A, et al.Analysis of the efficacy and toxicity of sorafenib in thyroid cancer:a phaseⅡstudy in a UK based population[J].Eur J Endocrinol, 2011, 165(2):315-322.
26. Schlumberger MJ, Elisei R, Bastholt L, et al.PhaseⅡstudy of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer[J].J Clin Oncol, 2009, 27(23):3794-3801.
27. Cohen EE, Rosen LS, Vokes EE, et al.Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer:results from a phaseⅡstudy[J].J Clin Oncol, 2008, 26(29):4708-4713.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Targeted Therapies for Medullary Thyroid Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content